IL1B and COVID-19: This phenomenon is characterized by the production of high levels of inflammatory mediators (e.g., interferons, TNFα, interleukin 1 beta - IL-1β, IL-6, and IL-10), chemokines, and colony-stimulating factors (CSFs; Tisoncik et al., 2012; Coperchini et al., 2020), which are increased in patients with severe forms of COVID-19 (Henry et al., 2020; Huang et al., 2020; McGonagle et al., 2020).